Testing for KIT and PDGFRA mutations is one of the most established molecular workflows in sarcoma care, because these two genes drive the large majority of gastrointestinal stromal tumors (GIST). For laboratories and distributors, sourcing a focused two-gene test is attractive: the clinical rationale is strong, the guideline backing is explicit, and the result directly influences whether a patient is offered a tyrosine kinase inhibitor such as imatinib. That clarity makes it one of the easier molecular assays to introduce into a routine menu.
According to NCCN guidance, roughly 80 percent of GISTs carry an activating mutation in KIT, and about 5 to 10 percent carry a PDGFRA mutation; the remaining tumors may involve other drivers. Because both KIT and PDGFRA encode receptor tyrosine kinases, their mutant forms produce constitutive signaling that imatinib and related agents are designed to block. NCCN recommends KIT and PDGFRA testing when tyrosine kinase inhibitor therapy is being considered, which makes the test a near-routine step rather than an optional add-on, and a predictable source of referral volume for the lab.
The two-gene test can be performed by Sanger sequencing, targeted PCR, or next-generation sequencing, depending on the lab's platform and the depth required. The standard specimen is FFPE tumor tissue from the GIST resection or biopsy, and quality depends on adequate tumor content. Buyers should confirm which alteration types the method reports, point mutations versus copy changes, and whether the lab distinguishes PDGFRA exon 18 changes, which carry different therapy implications and should not be reported as uniformly imatinib-sensitive.
Beyond price, evaluate the lab's quality accreditation, turnaround, and report structure. A useful report states the specific exon and mutation, interprets it in plain language, and notes the relevant therapy implication. For distributors, also confirm kit stability, shipping requirements, and whether the supplier offers clinician support so the result is acted upon correctly, since a technically accurate but poorly explained report can still stall patient care.
Q: Why test only two genes in GIST? A: Because KIT and PDGFRA account for the overwhelming majority of GIST drivers and directly determine tyrosine kinase inhibitor suitability.
Q: Does a negative KIT or PDGFRA result mean no targeted option exists? A: Not necessarily; NCCN notes that KIT or PDGFRA-negative GISTs should be assessed with broader testing for alternative drivers.
Q: What specimen is needed for this test? A: Typically FFPE tumor tissue from the GIST, with sufficient tumor content for reliable mutation calling.
Testing for KIT and PDGFRA mutations is one of the most established molecular workflows in sarcoma care, because these two genes drive the large majority of gastrointestinal stromal tumors (GIST). For laboratories and distributors, sourcing a focused two-gene test is attractive: the clinical rationale is strong, the guideline backing is explicit, and the result directly influences whether a patient is offered a tyrosine kinase inhibitor such as imatinib. That clarity makes it one of the easier molecular assays to introduce into a routine menu.
According to NCCN guidance, roughly 80 percent of GISTs carry an activating mutation in KIT, and about 5 to 10 percent carry a PDGFRA mutation; the remaining tumors may involve other drivers. Because both KIT and PDGFRA encode receptor tyrosine kinases, their mutant forms produce constitutive signaling that imatinib and related agents are designed to block. NCCN recommends KIT and PDGFRA testing when tyrosine kinase inhibitor therapy is being considered, which makes the test a near-routine step rather than an optional add-on, and a predictable source of referral volume for the lab.
The two-gene test can be performed by Sanger sequencing, targeted PCR, or next-generation sequencing, depending on the lab's platform and the depth required. The standard specimen is FFPE tumor tissue from the GIST resection or biopsy, and quality depends on adequate tumor content. Buyers should confirm which alteration types the method reports, point mutations versus copy changes, and whether the lab distinguishes PDGFRA exon 18 changes, which carry different therapy implications and should not be reported as uniformly imatinib-sensitive.
Beyond price, evaluate the lab's quality accreditation, turnaround, and report structure. A useful report states the specific exon and mutation, interprets it in plain language, and notes the relevant therapy implication. For distributors, also confirm kit stability, shipping requirements, and whether the supplier offers clinician support so the result is acted upon correctly, since a technically accurate but poorly explained report can still stall patient care.
Q: Why test only two genes in GIST? A: Because KIT and PDGFRA account for the overwhelming majority of GIST drivers and directly determine tyrosine kinase inhibitor suitability.
Q: Does a negative KIT or PDGFRA result mean no targeted option exists? A: Not necessarily; NCCN notes that KIT or PDGFRA-negative GISTs should be assessed with broader testing for alternative drivers.
Q: What specimen is needed for this test? A: Typically FFPE tumor tissue from the GIST, with sufficient tumor content for reliable mutation calling.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
